Abstract
Objective
The objective of this study is to evaluate the efficiency of SOD applied topically in oncologic patients affected by acute radiodermatitis.
Materials and method
This study includes 57 patients who showed a dermatitis grade 2 or superior; they were administered SOD ointment b.i.d. (40 mg, weekly) and follow-up continued for 12 weeks.
Results
At the end of radiotherapy, 77.1% of the patients ameliorated completely or partially, and at the end of the 12-week period 100% of patients were free of toxicity. No acute toxicity relapses were reported. Response time reduced during radiotherapy, as well as the treatment time at the end of it.
Conclusions
The employment of SOD topically is efficient in the treatment of radiodermatitis, which is an acute side effect of radiotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nakano T, Oka K, Taniguchi N (1996) Manganese superoxide dismutase expression correlates with p53 status and local recurrence of cervical carcinoma treated with radiation therapy. Cancer Res 56:2771–2775
Buell MG, Hording RK (1989) Proinflammatory effects of local abdominal irradiation on rat GI tract. Dig Dis Sci 34:390–399
De AK, Rajan RR, Krishnamoorthy L et al (1995) Oxidative stress in radiation-induced interstitial pneumonitis in the rat. Int J Radiat Biol 68:405–409
Epperly M, Bray J, Kraeger S et al (1998) Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gen Ther 5:196–208
McCord JM, Fridovich I (1969) Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049–6055
Esco R, Valencia J, Bascon N et al (2003) Prevención de toxicidad rectal tardía radioinducida. Estudio randomizado. Rev Oncología 5:190
Esco R, Valencia J, Bascon N et al (2003) Estudio randomizado de prevención de toxicidad radioinducida tardía pélvica mediante Ontosein®. Rev Oncología 5:190
Valencia J, Polo S, Velilla C et al (2001) Impacto del uso de orgoteina en la prevención de esofagitis por irradiación en el carcinoma microcítico pulmonar. Rev Oncología 3:204
Valencia J, Polo S, Bascon N et al (2000) Orgoteina asociada a radioterapia en cancer de cabeza y cuello. Control de la toxicidad. Rev Oncología 2:137
Edsmyr F, Menander Huber KB (1981) Orgotein efficacy in ameliorating side effects due to radiation therapy. Eur J Rheum Inflamm 4:228–236
Edsmyr F, Huber W, Menander KB (1976) Orgotein efficacy in ameliorating side effects due to radiation therapy. Double-blind, placebo-controlled trial in patients with bladder tumors. Curr Ther Res 19:198–211
Maberger H, Hubert W, Menandert Hubert KB, Bartsch G (1981) Orgotein: a new drug for the treatment of radiation cystitis. Eur J Rheum Inflamm 4:244–249
Menander Huber KB, Edsmyr F, Huber W (1980) Orgotein efficacy in ameliorating side effects due to radiation therapy. Scand J Urol Nephrol 55:219–224
Vaca JM, Vegas M, Merino R (1997) Epidural orgotein in failed back syndrome. II Congress of the European Federation of IAPS 1997. Barcelona, Spain
Ruiz A, Gil R (1999) Tratamiento del dolor mediante administración intradérmica de una solución compuesta por anestésico local+antiinflamatorio+analgésico. IV congreso de la SED, Málaga, Spain
Reig E (1994) Sistemas de infusión de fármacos en el tratamiento del dolor. Rev Soc Esp Dolor 1:14–20
Rodríguez-López M, Camba A, Contreras D, Torres LM (2003) Multicenter clinical trial of epidural orgotein versus placebo in patients with chronic intractable spinal pain. Pain Clin 15:7–15
Rubin P, Constine LS, Fajardo LF et al (1995) Overview: late effects of normal tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 3:1041–1042
Cox JD, Stetz JA, Pajak TF (1995) Toxicity criteria of radiation therapy oncology group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346
Fuentes R, Canals E, Vayreda J (2003) Tratamientos de soporte en oncología radioterápica. Servicio de Oncología Radioterápica. Institut Catalá d’Oncologia, Girona (9):40–43
Sanchiz F, Millá A (1996) Prevention with orgotein of radioinduced secondary effects in patients with head and neck tumours. VIII Biennial Meeting International Society for Free Radical Research, Paris, France
Perderau B, Campana F, Vilcoq JR et al (1994) Superoxyde dismutase (Cu/Zn) en application cutanée dans le traitment des fibrose radioinduites. Bull Cancer 81:659–669
Benyahia B, Campana F, Perderau B et al (1996) Effects of superoxide dismutase topical treatment on human skin radiofibrosis: a pathological study. Breast 5:75–81
Campana F, Zervoudis S, Perdereau B et al (2004) Topical superoxide dismutase reduces post-irradiation breast cancer fibrosis. J Cel Mol Med 8:109–116
Valencia J, Bascon N, Polo S et al (2000) Orgotein impact on radiotherapy acute side effects in head and neck cancer. Radiother Oncol 56:411
Valencia J, Velilla C, Urpegui A et al (2002) The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 88:385–389
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García, Á.M., López Carrizosa, M.C., Vallejo Ocaña, C. et al. Superoxidase dismutase (SOD) topical use in oncologic patients: treatment of acute cutaneous toxicity secondary to radiotherapy. Clin Transl Oncol 10, 163–167 (2008). https://doi.org/10.1007/s12094-008-0174-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0174-0